14.2 ED Workflow, Transitions of Care & Boarding Patient Management

14.2 ED Workflow, Transitions of Care & Boarding Patient Management

The ED Boarding Crisis & Patient Safety Dynamics

Emergency department (ED) boarding is defined as the condition wherein a patient has received a formal medical decision to be admitted to an inpatient bed but remains physically accommodated within the emergency department due to a complete lack of available inpatient inpatient capacity. Boarding represents an operational failure of hospital-wide throughput rather than an isolated ED issue, creating profound clinical hazards for boarding patients and newly presenting emergency arrivals alike.

Clinical Impact of Crowding and Boarding

1. Medication Administration Delays: Boarding patients experience prolonged delays in receiving critical scheduled home medications and newly ordered inpatient pharmacotherapy. Inpatient orders placed in the electronic health record (EHR) often default to standard inpatient administration times (e.g., 09:00 or 17:00), which may leave an ED boarding patient waiting 8 to 14 hours for their initial inpatient doses unless an emergency pharmacist manually adjusts administration schedules.
2. Escalated Medication Error Rates: The physical environment of the ED is designed for short-term diagnostic stabilization, not continuous inpatient nursing care. ED nurse-to-patient staffing ratios in crowded departments frequently rise from 1:3 to 1:6 or higher. Under these conditions, studies report substantially more wrong-dose, wrong-time and omitted-dose errors.
3. Increased Inpatient Mortality: Multiple landmark epidemiologic investigations demonstrate that prolonged ED boarding (>6 to 12 hours) is associated with higher in-hospital mortality in multiple observational studies, prolonged hospital length of stay (LOS), higher rates of secondary hospital-acquired infections, and increased frequency of unexpected ICU transfers occurring within 24 hours of leaving the ED.

---

High-Risk Transitions of Care & Medication Reconciliation

Transitions of care are vulnerable clinical intersections where communication breakdowns, fragmented information, and shifting clinical responsibilities generate over 50% of all hospital medication errors. The emergency department sits at the epicenter of three high-risk transitions: Community-to-ED (Triage/Arrival), ED-to-Inpatient (Admission Transfer), and ED-to-Home (Discharge).

The Best Possible Medication History (BPMH)

A Best Possible Medication History (BPMH) is a systematic interview and verification process that obtains the most accurate list possible of all medications the patient is currently taking, including drug name, dosage, route, frequency, and time of last dose.

• The Multi-Source Rule: A valid BPMH requires consulting at least two independent sources. Relying solely on patient recall or an outdated EHR list is insufficient.
• Primary Verification Sources:
  1. Comprehensive, structured patient or caregiver interview.
  2. Outpatient community pharmacy dispensing records (obtained via direct telephone verification or state/regional health information exchange [HIE] pharmacy fill data).
  3. State Prescription Drug Monitoring Program (PDMP) databases (mandatory for controlled substances).
  4. Outpatient specialty clinic notes (e.g., oncology, transplant, nephrology records).
  5. Physical inspection of pill bottles brought to the emergency department.

                  BEST POSSIBLE MEDICATION HISTORY (BPMH) WORKFLOW
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ Step 1: Structured Patient / Caregiver Interview                            │
  │ Cross-examine prescription drugs, OTCs, herbals, and PRN medications        │
  └──────────────────────────────────────┬──────────────────────────────────────┘
                                         ▼
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ Step 2: Corroboration via Secondary Objective Source                        │
  │ Retail pharmacy fill history | State PDMP | Electronic health network       │
  └──────────────────────────────────────┬──────────────────────────────────────┘
                                         ▼
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ Step 3: Reconciliation Against Inpatient Admission Orders                   │
  │ Identify intentional vs unintentional discrepancies (omissions, duplications)│
  └──────────────────────────────────────┬──────────────────────────────────────┘
                                         ▼
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ Step 4: Active Communication & Clarification with Inpatient Provider Team   │
  │ Convert oral regimens to IV equivalents when NPO; resume critical basals    │
  └─────────────────────────────────────────────────────────────────────────────┘

---

Identification of High-Risk Medication Omissions in Boarding Patients

When admitted patients board in the ED for extended durations, non-urgent home medications are frequently discontinued or omitted pending inpatient physician team rounds. For specific therapeutic drug classes, omission is not benign; it is immediately life-threatening.

The Five Critical Omission Classes

1. Antiepileptic Drugs (AEDs: Levetiracetam, Valproate, Phenytoin, Lacosamide, Carbamazepine):
   • Pathophysiology: Antiepileptic agents maintain steady-state serum concentrations to suppress paroxysmal neuronal hypersynchrony. Missing even a single scheduled dose can cause serum drug concentrations to drop below the minimum effective threshold, precipitating breakthrough seizures or refractory status epilepticus.
   • Pharmacist Action: Reconcile home AED regimens immediately. If the patient is NPO, convert oral formulations to equivalent intravenous dosing (e.g., levetiracetam 1:1 oral to IV, valproate 1:1 oral to IV, lacosamide 1:1 oral to IV). For phenytoin, utilize fosphenytoin IV (1 mg phenytoin equivalent [PE] per 1.5 mg fosphenytoin) to prevent tissue necrosis associated with propylene glycol diluents.
2. Antiretroviral Therapy (ART for HIV Infection):
   • Pathophysiology: HIV replication kinetics are exceptionally rapid. Incomplete adherence or brief interruptions in combination antiretroviral therapy (cART) allow viral rebound and provide selective pressure that fosters irreversible, multidrug-resistant viral mutations.
   • Pharmacist Action: Never hold ART pending general floor transfer. Never administer partial regimens (e.g., giving 1 drug of a 3-drug fixed-dose single-tablet regimen). Confirm the exact regimen (e.g., Biktarvy [bictegravir/emtricitabine/tenofovir alafenamide], Triumeq [abacavir/dolutegravir/lamivudine]) and ensure immediate dispensing from central pharmacy stock.
3. Solid Organ Transplant Immunosuppressants (Tacrolimus, Cyclosporine, Mycophenolate):
   • Pathophysiology: Calcineurin inhibitors (tacrolimus, cyclosporine) and antimetabolites (mycophenolate mofetil) possess exceptionally narrow therapeutic indices. Rapid drop in trough levels precipitates acute allograft rejection (renal, cardiac, hepatic, or pulmonary), leading to irreversible organ graft failure.
   • Pharmacist Action: Check 12-hour trough levels immediately if due. If the patient cannot tolerate oral intake, convert tacrolimus to continuous intravenous infusion at one-third to one-fourth (1:3 to 1:4) of the total daily oral dose (due to significant oral first-pass metabolism), administered over 24 hours in a glass or non-PVC container with dedicated IV tubing.
4. Basal Insulin in Type 1 Diabetes Mellitus (Insulin Glargine, Detemir, Degludec):
   • Pathophysiology: In Type 1 Diabetes, absolute endogenous insulin deficiency exists. Basal insulin is required continuously to suppress lipolysis, free fatty acid oxidation, and hepatic ketogenesis. A common, severe clinical misconception is holding basal insulin when a patient is placed on "NPO" status. Withholding basal insulin in a T1D patient triggers acute ketoacidosis (DKA) within 12 to 18 hours, even if blood glucose remains only mildly elevated.
   • Pharmacist Action: Ensure basal insulin is continued in all Type 1 diabetic patients regardless of NPO status. The basal dose may be cautiously reduced by 20% to 30% if caloric intake is strictly withheld, but basal insulin must never be discontinued entirely.
5. Chronic Beta-Blockers (Metoprolol Succinate, Carvedilol, Propranolol, Atenolol):
   • Pathophysiology: Chronic beta-adrenergic blockade induces compensatory up-regulation and hypersensitization of beta-1 and beta-2 adrenergic receptors. Abrupt cessation leads to uncontrolled adrenergic hyperstimulation, manifesting as rebound tachycardia, hypertensive crisis, acute myocardial ischemia, unstable angina, and malignant ventricular dysrhythmias.
   • Pharmacist Action: Verify home beta-blocker dosing and resume therapy. If oral intake is prohibited, convert oral metoprolol tartrate or succinate to intravenous metoprolol tartrate (approximate 2.5:1 conversion ratio: 5 mg IV metoprolol every 6 hours is roughly equivalent to 25 mg PO metoprolol tartrate twice daily).

---

High-Risk Boarding Medication Interventions

---

Emergency Medicine Pharmacist (EMP) Direct Clinical Roles

The presence of dedicated, board-certified emergency medicine clinical pharmacists provides direct, tangible improvements in patient survival, resuscitation efficiency, and medication safety.

Bedside Resuscitation Team Member

• Cardiopulmonary Arrest (ACLS): The EMP actively manages resuscitation pharmacotherapy at the bedside: preparing and administering exact weight-based epinephrine, amiodarone, or lidocaine; ensuring appropriate flush volumes (20 mL saline flush following peripheral push); tracking cumulative epinephrine timing (every 3 to 5 minutes); anticipating reversible etiologies ("H's and T's"); and preparing calcium chloride, sodium bicarbonate, or lipid emulsion when toxicology or hyperkalemia is suspected.
• Acute Ischemic Stroke: The EMP verifies inclusion/exclusion criteria, screens for recent anticoagulant exposure, calculates exact weight-based dosing for tenecteplase (0.25 mg/kg IV bolus, maximum 25 mg) or alteplase (0.9 mg/kg IV, 10% bolus over 1 min, 90% infusion over 60 min, maximum 90 mg), and administers antihypertensive infusions (nicardipine, clevidipine, labetalol) to achieve target blood pressure (<185/110 mmHg pre-thrombolytic; <180/105 mmHg post-thrombolytic), dramatically reducing door-to-needle (DTN) times.
• Rapid Sequence Intubation (RSI): The EMP assesses patient hemodynamics, shock index, and airway anatomy; selects hemodynamically neutral induction agents (e.g., ketamine or etomidate); calculates ideal versus actual body weight doses for paralytics (rocuronium 1.2 mg/kg or succinylcholine 1.5 mg/kg); and immediately prepares post-intubation analgosedation infusions to prevent awake paralysis.
• Trauma & Massive Transfusion: The EMP coordinates rapid activation of massive transfusion protocols (MTP); prepares and administers tranexamic acid (TXA) (1 g IV over 10 minutes within 3 hours of injury, followed by 1 g IV over 8 hours); and manages rapid reversal of pre-injury anticoagulants (4F-PCC, vitamin K, idarucizumab).

Prospective Order Verification & Antimicrobial Stewardship

• Real-Time Order Screening: Prospective verification intercepts fatal prescribing errors before drug administration. EMPs screen for renal dosing adjustments, therapeutic duplications, drug-drug interactions, and documented anaphylactic allergies.
• Bedside Antimicrobial Optimization: EMPs guide early sepsis empiric antimicrobial selection based on local antibiograms; optimize pharmacokinetics through loading doses (vancomycin 25-30 mg/kg) and extended-infusion beta-lactams; and coordinate rapid diagnostic platforms (e.g., blood culture PCR, MRSA nasal swabs) to de-escalate broad-spectrum therapies within hours.
• Clinical Toxicology Consultations: EMPs rapidly evaluate acute toxidromes, recommend targeted laboratory diagnostics, calculate complex antidote infusions (N-acetylcysteine, fomepizole, digoxin Fab, high-dose insulin euglycemia [HIET]), and coordinate care with regional poison control centers.

---

Discharge Prescribing Stewardship & Culture Callback Systems

Discharge from the emergency department is a critical juncture where inappropriate prescribing choices can lead to patient harm, outpatient treatment failure, or rapid ED recidivism.

Acute Opioid Stewardship Guidelines

Prescribing opioids for acute painful conditions in the ED must comply with evidence-based CDC and ACEP clinical guidelines:

• Limiting Duration of Supply: For acute non-cancer pain, outpatient opioid prescriptions must be strictly limited to ≤3 to 7 days supply (typically ≤3 days is sufficient for most acute musculoskeletal or minor trauma pain).
• Immediate-Release Only: Only immediate-release (IR) formulations should be prescribed (e.g., oxycodone 5 mg PO or hydrocodone/acetaminophen 5/325 mg PO). Extended-release/long-acting (ER/LA) opioids (such as OxyContin, MS Contin, or transdermal fentanyl) are absolutely contraindicated for acute pain in opioid-naive patients.
• Mandatory PDMP Review: Clinicians must query the state Prescription Drug Monitoring Program (PDMP) prior to prescribing controlled substances to identify concurrent opioid prescriptions, undisclosed sedatives, or patterns of multiple-provider episodes.
• Naloxone Co-Prescribing: The 2022 CDC opioid prescribing guideline recommends offering take-home naloxone (for example, 4 mg nasal spray, now also available over the counter) when overdose risk is increased, including when:
  1. The prescribed daily opioid dose reaches or exceeds 50 Morphine Milligram Equivalents (MME)/day.
  2. The patient is concurrently prescribed a benzodiazepine, gabapentinoid, or other central nervous system depressant.
  3. The patient has a documented history of substance use disorder (SUD) or prior opioid overdose.
  4. The patient has underlying chronic respiratory disease (e.g., severe COPD, obstructive sleep apnea).

ED Discharge Culture Callback Programs

Emergency patients discharged home on empiric antimicrobials require proactive microbiological follow-up. An emergency-pharmacist-led culture callback program systematically reviews all positive urine, blood, wound, and respiratory cultures 24 to 72 hours post-discharge:

• Identification of Discordance: Compare isolated bacterial sensitivities against the discharge empiric prescription (e.g., patient discharged on cephalexin, but urine culture grows Enterobacter cloacae or ESBL-producing E. coli resistant to cephalexin).
• Clinical Contact & Intervention: Contact the patient via telephone to evaluate clinical symptom resolution. If asymptomatic and bacteruria was present without systemic symptoms, therapy may be discontinued. If symptomatic and the organism is resistant, the pharmacist contacts the patient's community pharmacy to change the antibiotic to a targeted, susceptible oral agent (e.g., nitrofurantoin or ciprofloxacin) or directs the patient back to the ED if systemic red-flag symptoms (fever, rigors, flank pain, hypotension) have emerged.

High-Risk Discharge Medication Counseling

• Direct Oral Anticoagulants (DOACs: Apixaban, Rivaroxaban): Counsel on exact dosing schedules, taking rivaroxaban with food, managing missed doses, avoiding over-the-counter NSAIDs and aspirin without medical direction, and recognizing signs of major bleeding.
• Insulin Regimens: Verify that the patient has access to needles, testing supplies, and a functional glucometer. Demonstrate insulin pen device technique and provide structured education on the "Rule of 15" for hypoglycemia: consume 15 grams of fast-acting carbohydrate (e.g., 4 oz fruit juice or 3-4 glucose tablets), recheck blood glucose in 15 minutes, and repeat if glucose remains <70 mg/dL.

---

Interprofessional Communication Tools: SBAR & I-PASS

Standardized communication structures eliminate ambiguity during high-velocity clinical handoffs and emergency escalations.

The SBAR Framework (Situational Escalation)

The I-PASS Framework (Standardized Shift & Boarding Handoff)

• I - Illness Severity: Categorize patient acuity (e.g., "Stable", "Watcher", "Unstable").
• P - Patient Summary: Succinct narrative of events leading to ED admission, active diagnoses, and current clinical course.
• A - Action List: Specific time-sensitive tasks to be completed (e.g., "Recheck potassium at 14:00", "Follow up CT abdomen report").
• S - Situation Awareness & Contingency Planning: "If-Then" guidance anticipating clinical deterioration (e.g., "If blood pressure drops below 90 mmHg MAP, initiate norepinephrine infusion at 5 mcg/min and notify ICU").
• S - Synthesis by Receiver: The receiving clinician provides a brief read-back summarizing the critical action items and contingency plans, ensuring closed-loop communication.